Treatments for COPD, psoriasis, and neuroendocrine tumors, as well as a next-generation COVID-19 vaccine are under review.

The EMA has agreed to review GSK’s application to expand Nucala’s use as an add-on maintenance for individuals with COPD.

(Alliance News) - GSK PLC on Monday said it has had an application to expand the use of mepolizumab for the treatment of chronic obstructive pulmonary disease accepted for review by the European ...

EMA accepts for review GSK’s application to expand use of Nucala for COPD treatment: London, UK Wednesday, March 26, 2025, 11:00 Hrs [IST] GSK plc announced that the European Me ...

The FDA is reviewing the BLA for mepolizumab, an interleukin-5 (IL-5) antagonist monoclonal antibody, as an add-on maintenance treatment for chronic obstructive pulmonary disease (COPD ...

GSK said on Monday that the European Medicines Agency has accepted its application to expand the use of ‘Nucala’, or mepolizumab, to include patients with chronic obstructive pulmonary disease (COPD) ...

Patients with severe asthma initiated dupilumab and tezepelumab treatment more often than other biologics between 2022 and ...

Patients began with mepolizumab or benralizumab before switching to continuing with benralizumab at week 52. About 44% of patients stopped using oral glucocorticoids. Blood eosinophil counts fell ...

The MANDARA clinical trial was a 52-week, randomized, double-blind, active-controlled, head-to-head noninferiority trial comparing the efficacy and safety of FASENRA to mepolizumab in adult ...

The active ingredient in Nucala is mepolizumab. (An active ingredient is what makes a drug work.) Nucala is given as an injection under your skin. A healthcare professional may give you these ...